PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'BCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada; Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada.\', \'Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada; BC Children\'s and Women\'s Hospital, Vancouver BC, Canada.\', \'BC Children\'s and Women\'s Hospital, Vancouver BC, Canada; Department of Laboratory Medicine, Providence Health Care, Vancouver BC, Canada.\', \'BCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada.\', \'Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada; Surrey Memorial Hospital, Surrey BC, Canada.\', \'Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada; Vancouver General Hospital, Vancouver BC, Canada.\', \'Provincial Health Services Authority, Vancouver BC, Canada.\', \'Vancouver Coastal Health, Vancouver BC, Canada.\', \'BCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada; Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada. Electronic address: Muhammad.Morshed@bccdc.ca.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1386-6532(21)00181-510.1016/j.jcv.2021.104914
?:hasPublicationType
?:journal
  • Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
is ?:pmid of
?:pmid
?:pmid
  • 34304088
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • SARS-CoV-2 serology: Validation of high-throughput chemiluminescent immunoassay (CLIA) platforms and a field study in British Columbia.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all